Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil

Table 3 Sociodemographic, clinical and treatment characteristics of ulcerative colitis and Crohn’s disease patients at the index date according to the final disease activity assessment

Characteristics at index date	CD patients (n = 82)			UC patients (n = 25)
	Moderate-to-severe activity (n = 18)	No or mildactivity (n = 64)	P value	Moderate-to-severe activity (n = 5)	No or mild activity (n = 20)	P value
Age (yr), mean ± SD	42.0 ± 13.0	43.1 ± 12.7	0.7323	38.0 ± 14.4	46.9 ± 17.5	0.3104
Female, n (%)	12 (66.7)	39 (60.9)	0.7865	4 (80.0)	15 (75.0)	> 0.9995
Employed, n (%)	4 (23.5)	22 (45.8)	0.3286	1 (20.0)	2 (10.5)	0.9775
Attended higher education, n (%)	2 (12.5)	20 (42.6)	0.0296	1 (20.0)	2 (18.2)	0.4625
Body Mass Index (kg/m2), mean ± SD	27.5 ± 3.7	24.2 ± 4.4	0.0074	25.4 ± 7.5	24.8 ± 5.5	0.8383
Current smokers, n (%)1	2 (12.5)	4 (7.0)	0.6075	0 (0.0)	0 (0.0)	NA
IBD duration (yr), median (IQR)	6.0 (1-27)	13.0 (0-45)	0.04333	5 (1-23)	6.5 (1-23)	0.70324
Time since moderate to severe IBD (yr), median (IQR)	5.5 (1-25)	7.0 (0-26)	0.88393	2 (0-18)	3.5 (1-16)	0.81013
Extra intestinal manifestation, n (%)	3 (50.0)	17 (51.5)	0.9466	1 (33.3)	4 (40.0)	NA
HBI result, median (IQR)	9.0 (7-13)	4.0 (1-8)	NA	-	-	-
CDAI result, median (IQR)	200.0 (114-311)	224.0 (113-281)	NA	-	-	-
Previous calprotectin level > 200 µg/g, n (%)	3 (16.7)	24 (37.5)	0.0976	-	-	-
Previous colonoscopy with CD activity, n (%)	12 (66.7)	33 (51.6)	0.2566	-	-	-
Ileocolonic disease, n (%)	13 (72.2)	36 (56.3)	0.2825	-	-	-
Stricturing or penetrating CD behavior, n (%)	11 (61.1)	48 (75.0)	0.2476	-	-	-
Symptomatic perianal disease, n (%)	10 (55.6)	19 (30.2)	0.0666	-	-	-
Partial Mayo score, median (IQR)	-	-	-	7.0 (5-8)	6.0 (5-6)	NA
Left-sided or pancolitis UC, n (%)	-	-	-	3 (60.0)	15 (75.0)
Current IBD treatment at baseline2, n (%)	15 (83.3)	61 (95.3)	0.2335	5 (100.0)	19 (95.0)	0.8715
Treatment ongoing or initiated at index, n (%)	16 (88.9)	62 (96.9)	0.4165	5 (100.0)	20 (100.0)	NA
5-ASA compounds	2 (12.5)	10 (16.1)	3 (60.0)		16 (80.0)
Biologic therapy	13 (81.3)	41 (66.1)	3 (60.0)		4 (20.0)
Corticosteroids	3 (18.8)	9 (14.5)	3 (60.0)		9 (45.0)
Immunosuppressants	5 (31.3)	44 (71.0)	3 (60.0)		10 (50.0)

¹Smoking at Day 1 and has smoked 100 cigarettes in his/her lifetime.

²Ongoing or discontinued at baseline.

³P values from theMann-Whitney test.

⁴t-test.

⁵Fisher’s exact test.

⁶Chi-square test. SD: Standard deviation; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; HBI: Harvey-Bradshaw index; CDAI: Crohn’s disease activity index; pMayo: Partial Mayo score; 5-ASA: 5-aminosalicylate; NA: Not applicable.